We may be nearing a vaccine.
Just this morning, Moderna Inc. (MRNA) announced another $472 million commitment from the U.S. government to develop a vaccine. According to SVB Leerink analysts, that commitment will be used to fund a Phase 3 trial for Moderna’s vaccine, which is “set to begin immediately,” as quoted by MarketWatch.
In addition, according to the company, “The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health(NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.”
The company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.